Testosterone Cypionate Injectable Recalled for Lack of Sterility Assurance
Vita Pharmacy, LLC dba Talon Compounding Pharmacy is recalling Testosterone Cypionate 200mg/ml injectable due to lack of assurance of sterility. The product was distributed across the United States, including Washington, D.C. and Puerto Rico.
What this means for you
Illness, injury, or structural failure has been reported. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: This is an FDA Class II recall of a sterile injectable pharmaceutical product. Lack of sterility assurance in an injectable medication poses a significant risk of serious infection or other adverse health consequences, meeting the criteria for Severe classification.
Plain-English summary
Vita Pharmacy, LLC dba Talon Compounding Pharmacy is recalling Testosterone Cypionate 200mg/ml injectable in sesame oil due to lack of assurance of sterility. The recalled product is a prescription-only injectable medication distributed in vials.
The product was distributed across the United States, including Washington, D.C. and Puerto Rico. Multiple lot numbers are affected, with expiration dates ranging from October 2021 through March 2022.
Consumers who have received this product should contact their healthcare provider or pharmacist. Patients should not use the product and should consult with their medical professional regarding continuation of testosterone therapy through alternative sources.
The recalled product
- Product
- TESTOSTERONE CYPIONATE 200MG/ML INJ #2 IN SESAME OIL INJECTABLE, Rx only, Talon Compounding Pharmacy, 2950 Thousand Oaks Drive Ste 25, San Antonio, Texas 78247
- Manufacturer
- Vita Pharmacy, LLC dba Talon Compounding Pharmacy
- Category
- Drug — Injectable / Hormone
- Hazard
- sterility-assurance
- contamination-risk
- injection-infection-risk
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (9)
- Lot: T1007082021:20 BUD: 01/04/2022
- T0907262021:21 BUD: 01/04/2022
- T0506142021:81 BUD: 12/11/2021
- T104142021:49 BUD: 10/11/2021
- T1006022021:96 BUD: 11/29/2021
- T0507152021:79 BUD: 01/11/2022
- T1009082021:42 BUD: 03/07/2022
- T0508172021:37 BUD: 02/13/2022
- T0505112021:57 BUD: 10/11/2021
Distribution
Distribution scope not specified by the agency.
Related recalls
Same category
- CriticalWarfarin Tablets Recalled After Mix-Up Between 2.5 mg and 5 mg Strengths
FDA (Drugs) · 2026-07-21
- ModerateFDA Recalls Pred Mild Ophthalmic Suspension Due to Failed Stability Specifications
FDA (Drugs) · 2026-06-03
- ModerateNicotine Transdermal System Patches Recalled for Oxidative Impurity Specification Failure
FDA (Drugs) · 2026-06-03
- LowPrimidone Tablets Recalled Due to Cross-Contamination with Acemetacin
FDA (Drugs) · 2026-05-27
- HighLiraglutide Injection Recalled Due to Particulate Matter in Cartridges
FDA (Drugs) · 2026-05-27